11 Apr

Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical Officer

curevovaccine Press Releases No Comments
-- Dr. De La Rosa adds over 20 years of big pharma and biotech infectious disease clinical trial experience to Curevo Vaccine Seattle, WA – April 11, 2023 – Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced Dr. Guy De La Rosa has…
Continue Reading
Curevo Vaccine Receives 2022 Best of Bothell Award
12 Dec

Curevo Vaccine Receives 2022 Best of Bothell Award

curevovaccine Press Releases No Comments
Bothell Award Program Honors the Achievement BOTHELL December 12, 2022 -- Curevo Vaccine has been selected for the 2022 Best of Bothell Award in the Corporate Office category by the Bothell Award Program. Each year, the Bothell Award Program identifies companies that we believe have achieved exceptional marketing success in their local community and business category. These are local companies…
Continue Reading
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
16 Nov

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

curevovaccine Press Releases No Comments
-- Curevo’s lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has completed enrollment in a 678-patient Phase 2b head-to-head trial of CRV-101 against Shingrix® with data due early 2023 November 16, 2022 10:00 AM Eastern Standard Time SEATTLE--(BUSINESS WIRE)--Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing…
Continue Reading
Phase 2 Enrollment of CRV-101 Completed
15 Sep

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

curevovaccine Press Releases 9 Comments
-- Phase 2b trial enrolled 678 participants in six months -- Topline data from Phase 2b head-to-head trial of CRV‑101 against Shingrix® expected in early 2023 SEATTLE, Sept. 15, 2022 /PRNewswire/ -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced completion of enrollment in a Phase 2b trial of their CRV-101…
Continue Reading
Curevo history 450x249
11 Feb

Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot

curevovaccine News No Comments
SEATTLE–(GEEKWIRE)–Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup to test its vaccine against a market-commanding shot made by GlaxoSmithKline. Curevo’s upcoming phase 2b trial will compare safety of the two vaccines in more than 650 people, and assess immune…
Continue Reading
60 Million Funding Supports Shingles Vaccine Candidate 1200 x 800
11 Feb

$60 Million Funding Supports Shingles Vaccine Candidate

curevovaccine News, Vaccines No Comments
(Precision Vaccinations) Washington-based Curevo Vaccine today announced the closing of a $60 million Series A financing round that would support the 678-patient Phase 2b head-to-head clinical trial of the CRV‑101 shingles vaccine candidate against Shingrix®, from initiation through topline data. CRV-101 is a clinical-stage adjuvanted sub-unit vaccine specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of…
Continue Reading
Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines 658x324
10 Feb

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

curevovaccine News, Press Releases, Vaccines No Comments
SEATTLE–(BUSINESS WIRE)–Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round. “The upcoming Phase 2b trial is designed to compare CRV‑101’s immunogenicity and safety profile relative to Shingrix®. “I’m excited to close this financing and…
Continue Reading
George-Simeon 2048 x 1152
10 Feb

A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board

curevovaccine News, Vaccines No Comments
GlaxoSmithKline’s Shingrix has quickly become one of the company’s best-selling products since first winning FDA approval in 2017. But a new biotech believes it can do better — and RA Capital is listening. Curevo Vaccine, a Seattle-based company, debuted a $60 million Series A on Thursday led by the prominent life sciences VC, aiming to fund a Phase IIb study…
Continue Reading
Curevo Presenting at World Vaccine Conference Congress (Washington) 816x633
28 Sep

Curevo Presenting at World Vaccine Conference Congress (Washington) Sept 28 – Oct 1

curevovaccine Events, Vaccines No Comments
Curevo Vaccine’s Steve Reed, PhD, Scientific Advisory and Executive Board member, and Lisa Shelton, ARNP, Associated Director Clinical Operations,  will be presenting at World Vaccine Congress Wednesday, September 30 @ 4:50pm EST/1:50pm PST , on Low side-effect safety profile demonstrated in phase 1 trial of shingles vaccine candidate CRV-101.  Join us to hear about the safety and a sneak peek into the…
Continue Reading
Shingles Vaccine by Curevo 4480 x 6720
18 Mar

SAHPRA Approval Press Announcement 2021

curevovaccine News, Press Releases, Vaccines No Comments
CUREVO VACCINE ANNOUNCES THE APPROVAL TO CONDUCT A PHASE 1B CLINICAL TRIAL IN SOUTH AFRICA TO EVALUATE SAFETY AND IMMUNOGENICITY OF ITS ADJUVANTED SUBUNIT INVESTIGATIONAL VACCINE, CRV-101, AGAINST VARICELLA (CHICKENPOX) IN HIV-POSITIVE CHILDREN. Curevo Vaccine, a clinical-stage biopharmaceutical company combining excellence in protein and adjuvant biology to develop new generation sub-unit vaccines of global importance, announced today that approval was…
Continue Reading
1 2